Ftse Mib
32.665,21
-2,81%
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,12%
Bitcoin
66.146,39
0,21%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ BioXcel Therapeutics Inc (BTAI) BioXcel Therapeutics Inc (BTAI) Notizie

BioXcel Therapeutics Inc

BTAI
1,341
-0,069 (-4,89%)
15 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
12/6/202401:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/6/202401:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202413:30EDGAR2Form 424B7 - Prospectus [Rule 424(b)(7)]
28/5/202413:00GLOBEBioXcel Therapeutics to Present at Jefferies Global..
21/5/202413:00GLOBEBioXcel Therapeutics Announces Oral and Poster Presentations..
09/5/202415:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202413:12EDGAR2Form 8-K - Current report
09/5/202413:00GLOBEBioXcel Therapeutics Reports First Quarter 2024 Financial..
25/4/202413:00GLOBEBioXcel Therapeutics to Report First Quarter 2024 Financial..
24/4/202416:30GLOBEBioXcel Therapeutics Announces Late-Breaking Abstract on..
22/4/202413:00GLOBEBioXcel Therapeutics Announces Plan for Evaluating BXCL501..
10/4/202413:00GLOBEBioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal..
25/3/202412:00GLOBEBioXcel Therapeutics Announces $25 Million Registered Direct..
15/3/202412:00GLOBEBioXcel Therapeutics Announces European Patent Office’s..
12/3/202412:00GLOBEBioXcel Therapeutics Reports Financial Results for the..
01/3/202413:00GLOBEBioXcel Therapeutics to Report Fourth Quarter and Full Year..
14/2/202413:00EDGAR2Form 8-K - Current report
13/2/202415:00GLOBEBioXcel Therapeutics Announces Termination of Proposed..
12/2/202418:45EDGAR2Form 8-K - Current report
12/2/202413:14GLOBEBioXcel Therapeutics Receives FDA Fast Track Designation for..
08/2/202423:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/2/202422:53EDGAR2Form 8-K - Current report
08/2/202422:01GLOBEBioXcel Therapeutics Announces Proposed Public Offering
08/2/202413:08EDGAR2Form 8-K - Current report
06/2/202413:00GLOBEBioXcel Therapeutics Announces Completion of Patient..
05/2/202413:00GLOBEBioXcel Therapeutics Announces USPTO’s Allowance of Patent..
23/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
12/1/202422:16EDGAR2Form S-3 - Registration statement under Securities Act of..
18/12/202322:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202322:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202322:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202313:22EDGAR2Form 8-K - Current report
12/12/202313:00EDGAR2Form 8-K - Current report
12/12/202313:00GLOBEBioXcel Therapeutics Hosting Virtual Neuroscience R&D Day..
11/12/202313:00GLOBEBioXcel Therapeutics Strengthens Clinical Development..
06/12/202313:00EDGAR2Form 8-K - Current report
30/11/202313:00GLOBEBioXcel Therapeutics to Host Virtual Neuroscience R&D Day on..
13/11/202317:59EDGAR2Form RW WD - Withdrawal of Registration Withdrawal Request
13/11/202316:23EDGAR2Form RW - Registration Withdrawal Request
08/11/202313:00GLOBEBioXcel Therapeutics Reports Positive Overall Survival..
06/11/202313:00GLOBEBioXcel Therapeutics Announces Update on NIDA-funded Trial..
02/11/202311:01EDGAR2Form S-3 - Registration statement under Securities Act of..
31/10/202312:00GLOBEBioXcel Therapeutics to Report Third Quarter 2023 Financial..
30/10/202312:00GLOBEBioXcel Therapeutics Receives Permanent J-Code for IGALMI™..
25/10/202316:30APSStrong Open For Biotech Shares Following Phase 3 Comments
25/10/202313:00GLOBEBioXcel Therapeutics Announces Positive Findings from..
19/10/202322:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
10/10/202313:06EDGAR2Form 8-K - Current report
10/10/202313:00GLOBEBioXcel Therapeutics Reports Positive Overall Survival..
04/10/202313:05EDGAR2Form 8-K - Current report
Apertura: 1,40 Min: 1,34 Max: 1,41
Chiusura: 1,41

La tua Cronologia

NASDAQ
BTAI
BioXcel Therapeutics
BIT
P1JIP3
BNP Paribas Issuance
BIT
GS0161
Goldman Sachs
BIT
P1QZZ1
BNP Paribas Issuance
BIT
P1M3B9
BNP Paribas Issuance
BIT
P1T8N6
BNP Paribas Issuance
ASX
TLSLOF
BIT
P1LO43
BNP Paribas Issuance
BIT
P1ORO7
BNP Paribas Issuance
BINA
LTCBTC
Litecoin
BIT
P1IAA4
BNP Paribas Issuance
BIT
P1R9U1
BNP Paribas Issuance
BIT
P20QK6
NLBNPIT20QK6 20240621 34
LSE
BP76
Citi Fun 25
LSE
BK17
Citi Fun 24
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network